These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11347050)

  • 1. [Abnormal lipid metabolism in acromegaly].
    Inoue T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():162-6. PubMed ID: 11347050
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypertension in acromegaly].
    Kumagai H; Onami T; Iigaya K; Hayashi K; Saruta T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():508-11. PubMed ID: 15171425
    [No Abstract]   [Full Text] [Related]  

  • 3. The vascular complications of acromegaly.
    Bondanelli M; Zatelli MC; Ambrosio MR; degli Uberti EC
    J Endocrinol Invest; 2003; 26(8 Suppl):28-31. PubMed ID: 15233208
    [No Abstract]   [Full Text] [Related]  

  • 4. The neoplastic complications of acromegaly.
    Terzolo M; Daffara F; Reimondo G; Allasino B; Ventura M; Angeli A
    J Endocrinol Invest; 2003; 26(8 Suppl):32-4. PubMed ID: 15233209
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V; Esposito D; Lo Iudice G
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperlipidemia in patients with GH deficiency].
    Hizuka N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():167-71. PubMed ID: 11347051
    [No Abstract]   [Full Text] [Related]  

  • 7. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk.
    Maison P; Chanson P
    Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):650-1. PubMed ID: 17143307
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of octreotide on lipid metabolism in acromegaly.
    Cohen R; Chanson P; Bruckert E; Timsit J; Legrand A; Harris AG; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1992 Aug; 24(8):397-400. PubMed ID: 1526629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
    Lombardi G; Colao A; Marzullo P; Ferone D; Longobardi S; Esposito V; Merola B
    J Endocrinol; 1997 Oct; 155 Suppl 1():S33-7; discussion S39. PubMed ID: 9389993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acromegaly: effects on bone metabolism and mass.
    Bogazzi F; Cosci C; Sardella C; Martino E; Gasperi M
    J Endocrinol Invest; 2005; 28(10 Suppl):33-5. PubMed ID: 16550720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide stimulates insulin-like growth factor binding protein-1: a novel mechanism of drug action on acromegaly.
    Melmed S
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):65-9. PubMed ID: 7527593
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disturbances of lipid and lipoprotein metabolism in hypeprolactinemia and acromegaly].
    Medić-Stojanoska M; Pletikosić I
    Med Pregl; 2009; 62 Suppl 3():91-4. PubMed ID: 19702124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular complications in acromegaly.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery.
    Wu TE; Lin HD; Lu RA; Wang ML; Chen RL; Chen HS
    Growth Horm IGF Res; 2010 Dec; 20(6):411-5. PubMed ID: 20943425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly.
    McGregor AR; Troughton WD; Donald RA; Espiner EA
    Horm Metab Res; 1990 Jan; 22(1):55-6. PubMed ID: 1968417
    [No Abstract]   [Full Text] [Related]  

  • 18. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.
    Delaroudis SP; Efstathiadou ZA; Koukoulis GN; Kita MD; Farmakiotis D; Dara OG; Goulis DG; Makedou A; Makris P; Slavakis A; Avramides AI
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):279-84. PubMed ID: 18194486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis, evaluation and therapy of hyperlipidemia.
    Jordan RM
    J Ark Med Soc; 1987 Jun; 84(1):59-64. PubMed ID: 2956247
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetic ketoacidosis in a patient with acromegaly.
    Kopff B; Mucha S; Wolffenbuttel BH; Drzewoski J
    Med Sci Monit; 2001; 7(1):142-7. PubMed ID: 11208511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.